within Pharmacolibrary.Drugs.ATC.B;

model B02BD01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 6.166666666666667e-05,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 4e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B02BD01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>This combination is a prothrombin complex concentrate (PCC), comprised of human blood plasma-derived coagulation factors II, VII, IX, and X, typically used for the treatment and prevention of bleeding in patients with deficiency of multiple vitamin K-dependent clotting factors, such as in cases of warfarin reversal or hereditary deficiency. Prothrombin complex concentrates are still approved and in clinical use, such as in urgent reversal of anticoagulation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are variably reported for individual factors, but specific PK for the 4-factor PCC combination limited. Data below are representative values estimated for adult populations from published summaries and product monographs.</p><h4>References</h4><ol><li><p>Honickel, M, et al., &amp; Grottke, O (2016). Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. <i>Thrombosis and haemostasis</i> 115(2) 271–284. DOI:<a href=&quot;https://doi.org/10.1160/TH15-03-0266&quot;>10.1160/TH15-03-0266</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26333775/&quot;>https://pubmed.ncbi.nlm.nih.gov/26333775</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B02BD01;
